Effect of individualized treatment strategy on postoperative nausea and vomiting in gynaecological laparoscopic surgery: a double-blind, randomized, controlled trial

Wenjing Ma1†, Yupeng Qi2†, Can Liu1, Mingfang Wang1, Yun Zhang1 and Weidong Yao1*

Abstract

Background: Postoperative nausea and vomiting (PONV) have always been a concern of clinicians and may increase medical costs for patients. Consensus guidelines recommend using multiple antiemetics with different mechanisms as prophylaxis in patients at high risk of PONV. Individualized risk scores for nausea and vomiting and individualized treatment strategies are feasible. This study evaluated the effect of individualized treatment strategies on postoperative nausea and vomiting after laparoscopic gynaecological operations.

Methods: This was a double-blind, randomized, controlled trial. A total of 119 adult patients who underwent gynaecological laparoscopic surgery under general anaesthesia were randomly divided into an individualized treatment group or a control group, with the individualized treatment group receiving individualized prevention according to a preoperative risk score of nausea and vomiting and the control group receiving no individualized prevention. Vomiting, retching, nausea, and use of rescue medication were all recorded for 24 h after the operation. The primary outcome variable was complete response, defined as no emesis or the use of rescue medication 24 h postoperatively.

Results: The complete response rate was higher in the individualized treatment group (56.7%) than in the control group (23.7%) (95% CI, 0.01–0.27; \( P < 0.001 \)). The incidences of emesis (18.3% vs. 44.1%, \( P = 0.002 \)) were significantly lower in the individualized treatment group than in the control group. There were no differences in any nausea (26.7% vs. 33.9%, \( P = 0.391 \)) or rescue medication use (6.7% vs. 8.5%, \( P = 0.743 \)). Adverse events and laboratory and electrocardiogram abnormalities occurred no more frequently in the individualized treatment group than in the control group.

Conclusion: In conclusion, this single-centre, double-blind, randomized study suggests that an individualized PONV prophylactic treatment strategy based on the number of PONV risk factors could be a safe and effective regimen to reduce the incidence of PONV in adult patients undergoing laparoscopic gynaecological surgery.

Keywords: Postoperative nausea and vomiting, Gynaecological laparoscopic surgery, Individualized treatment strategy

Introduction

Postoperative nausea and vomiting (PONV) is one of the most frequent common complications of surgical procedures, occurring in approximately 30% of all surgical patients and more than 70% of certain high-risk patients [1–4]. The study by Kawano [5] showed that the
incidence of nausea or vomiting is approximately 72% in patients undergoing laparoscopic gynaecological surgery.

Patient-specific risk factors for PONV in adults include female sex, prior history of postoperative nausea and vomiting or motion sickness, nonsmoking, and the use of postoperative opioid analgesia [6–8]. The simplified risk score proposed by Apfel was widely used to predict patients’ risk for PONV. Consensus guidelines recommend using multiple antiemetics, including serotonin 5-HT₃, dopamine D₂ and histamine H₁ antagonists, and corticosteroids as prophylaxis in patients at high risk of PONV [9–12]. The latest PONV guidelines suggest the use of multimodal prophylaxis in patients with one or more risk factors [13]. It has been shown that antiemetics of different mechanisms provide additive benefits, each reducing the relative risk of PONV by approximately 25% [14].

Therefore, based on the above background, we proposed a simple and feasible treatment strategy for PONV based on the preoperative risk factor scores of nausea and vomiting to guide anaesthesiologists in the use of antiemetic drugs. We conducted this study to test the hypothesis that the individualized treatment strategy for nausea and vomiting when used can prevent postoperative nausea and vomiting in gynaecological laparoscopic surgery patients.

Methods
Study design
This prospective, double-blind, randomized, controlled trial was performed between July 2021 and February 2022 at the First Affiliated Hospital of Wannan Medical College, Wuhu, China. The study protocol was approved by the local Medical Ethics Committee (No. 2021–06). All of the patients were informed about the study and signed the informed consent form. The study was conducted following the Declaration of Helsinki. The trial was registered on Chictr.org before initiation on 20/06/2021, registration number ChiCTR2100047571 (http://www.chictr.org.cn/edit.aspx?pid=128533&htm=4).

Patient population
Eligible patients were 18–65 years of age; underwent elective laparoscopic gynaecological surgery under intravenous general anaesthesia, expected to last at least an hour; were classified as ASA I-II; were excluded if they had a known gastrointestinal disease; had taken antiemetic medication within 24 h before surgery; and were allergic to drugs.

Study treatments
The patients were randomly assigned to 1 of the 2 following groups according to the number (from 1–2) written inside the closed envelope and given the relevant medication. A computer-generated list of random numbers was used. Before surgery, the patients were evaluated according to Apfel risk factors for PONV: female sex, previous history of postoperative nausea and vomiting or motion sickness, being a nonsmoker, and expected use of postoperative opioids for analgesia [15]. In the individualized treatment group, patients were administered according to the number of risk factors for nausea and vomiting that existed before surgery. For patients with 1 risk factor, dexamethasone was given to them intravenously before the induction of anaesthesia. Patients with 2 risk factors were given two antiemetic medications, dexamethasone plus ondansetron or granisetron intravenously before abdominal closure. Patients with more than 3 risk factors were given three antiemetic medications, such as dexamethasone plus ondansetron or granisetron plus scopalamine. The control group was given one antiemetic drug.

All operations were performed by the same team of surgeons. Anaesthesia providers were not involved in collecting the outcome data. All of the drugs used in this study were prepared for administration by the same researcher who was not involved in the perioperative treatment of the patients. The medications and the syringes were similar in appearance with respect to colour and viscosity. Additionally, the anaesthesiologist and the surgeon were unable to see the composition of the solution injected into the operating theatre. The overall blinding process was implemented until all data had been entered into the database and their accuracy confirmed. Patients and all personnel involved in the trial conduct were blinded to the treatment assignment. Rescue antiemetic medication was to be given postoperatively to any patient with nausea or emesis, with the choice of agents being determined by the gynaecologist.

Perioperative management
Anaesthesia induction was achieved by using midazolam (0.05 mg/kg), sufentanil (0.3 μg/kg) and etomidate (0.3 mg/kg). Neuromuscular blockade was achieved by using rocuronium bromide (0.6 mg/kg IV), and endotracheal intubation was performed by inserting an orotracheal tube after sufficient muscular relaxation had been achieved. Anaesthesia was maintained with 0.1–0.2 μg/kg/min remifentanil intravenous (IV) infusion and 4–8 mg/kg/h propofol intravenous (IV) infusion. Rocuronium was statically administered intermittently to maintain muscle relaxation. After the completion of the surgery, patients with sufficient spontaneous respiration were extubated. The patients were then transferred to the postoperative anaesthesia care unit where they were monitored. Subsequently, the patients were transferred
to a gynaecology clinic, where they were followed for over 48 h.

**Evaluations**

The episodes of emesis (vomiting/retching), nausea, and rescue medication during the 24 h after the operation were recorded. Nausea was also assessed by direct questioning at 0–6, 6–12 and 12–24 h after the operation. The severity of nausea was evaluated on a PONV grading standard, with degree I representing no nausea or vomiting, degree II representing one or two episodes of nausea and vomiting, degree III representing three or four episodes of nausea and vomiting, and degree IV representing at least five episodes of nausea and vomiting. Complete response was defined as no emesis or the use of rescue medication within 24 h postoperatively. All adverse events were recorded from the administration of the study through discharge. Delayed recovery was defined as not being awake 90 min after anaesthesia. Arrhythmia is defined as QTc prolongation. The incidence of postoperative infection and hyperglycaemia (>6.0 mmol/L) was recorded.

The primary outcome was no emesis or the use of rescue medication 24 h postoperatively. Secondary outcomes included the severity of nausea and vomiting, the incidence of vomiting or nausea, and adverse events.

**Statistical analysis**

Based on the difference of 18% in the complete response rate of PONV, we determined that 102 patients in each group would be necessary to detect an 18% PONV with a power of 90% and a type I error of 0.05. To account for a potential 10% dropout rate, we enrolled 224 patients. Pearson’s chi-square test was used to assess the difference between two groups.

Statistical significance was calculated using log-rank tests. The severity of nausea was analysed using a Mann–Whitney test. Where appropriate, hypothesis testing was two-tailed with significance interpreted as $P < 0.05$. SPSS software (SPSS Institute, USA), version 22, was used for all data analyses.

**Results**

During the study period, 224 patients were assessed for eligibility, of whom 120 patients were enrolled in the trial. Among those 120 randomized patients, 60 patients were assigned to receive individual treatment, and 59 patients received one antiemetic drug (Fig. 1).

---

**Fig. 1** Flow diagram of the progression through the study
There was no significant difference between the two groups in age, BMI, history of PONV, history of motion sickness, nonsmoking, expected postoperative opioid use, or risk factors (Table 1).

Complete response occurred in 56.7% of the individualized treatment group and 23.7% of the control group (difference 33 percentage points; \( P < 0.001 \)) (Table 2). The incidence of complete response was higher in the individualized treatment group (90.9%) than in the control therapy group (22.2%) in two risk factor patients (\( P < 0.05 \)) (Table 2). However, the incidence of complete response in both three- and four-risk-factor patients was similar (Table 2).

The severity of nausea and vomiting in degrees II, III, and IV was higher in the control group than in the individualized treatment group (Table 3).

The incidence of emesis was significantly lower in the individualized treatment group (44.1%) than in the control therapy group (18.3%) (\( P < 0.001 \)) (Table 4).

Delayed recovery and postoperative infection and hyperglycaemia showed no differences between the two groups. Electrocardiogram data also showed no clinical relevant changes.

**Discussion**

The results of this study showed that compared with the patients in the control group (using one antiemetic drug), the severity and frequency of postoperative nausea

### Table 1: Demographic characteristics and risk factors for postoperative nausea and vomiting

|                          | Individualized treatment group \((n = 60)\) | Control group \((n = 59)\) | \( P \) |
|--------------------------|------------------------------------------|--------------------------|--------|
| Sex, female, n           | 60                                       | 59                       | 1.000  |
| Age, years, mean (SD)    | 43.3 (9.4)                               | 43.0 (9.0)               | 0.303  |
| ASA classification (1/2), n | 27/33                                    | 23/36                    | 0.579  |
| BMI, kg/m², mean (SD)    | 22.8 (2.7)                               | 22.8 (3.0)               | 0.782  |
| History of PONV, n (%)   | 9 (15.0)                                 | 8 (13.6)                 | 0.882  |
| History of motion sickness, n (%) | 21 (35.0) | 25 (42.4) | 0.409  |
| Nonsmoking, n (%)        | 59 (98.3)                                | 59 (100)                 | 1.000  |
| Expected postoperative opioid use, n (%) | 43 (71.7) | 42 (71.2) | 0.954  |

**Abbreviations:** SD Standard deviation, N Number

### Table 2: Complete response rates of risk factor classification

| Risk factors | Individualized treatment group \((n = 60)\) | Control group \((n = 59)\) | \( P \) |
|--------------|---------------------------------------------|---------------------------|--------|
| 1 risk factor, n (%) | 1 (1.7)                                    | 1 (1.7)                   | -      |
| 2 risk factors, n (%) | 11 (18.3)                                  | 9 (15.3)                  | -      |
| 3 risk factors, n (%) | 35 (58.3)                                  | 32 (54.2)                 | -      |
| 4 risk factors, n (%) | 13 (21.7)                                  | 17 (28.8)                 | -      |
| CR with all patients, n (%) | 34 (56.7)                                 | 14 (23.7)                 | < 0.001|
| CR with 1 risk factors, n (%) | 1 (100.0)                                 | 1 (100.0)                 | 1.000  |
| CR with 2 risk factors, n (%) | 10 (90.9)                                 | 2 (22.2)                  | 0.005  |
| CR with 3 risk factors, n (%) | 19 (54.3)                                 | 10 (31.3)                 | 0.050  |
| CR with 4 risk factors, n (%) | 5 (38.5)                                  | 2 (11.8)                  | 0.190  |

**Abbreviations:** CR Complete response

### Table 3: Comparison of the severity of nausea and vomiting

| Degree | Individualized treatment group \((n = 60)\) | Control group \((n = 59)\) | \( P \) |
|--------|---------------------------------------------|---------------------------|--------|
| I      | 36 (70.6)                                  | 15 (29.4)                 | < 0.001|
| II     | 14 (43.8)                                  | 18 (56.3)                 | 0.377  |
| III    | 5 (28.6)                                   | 5 (71.4)                  | 0.027  |
| IV     | 4 (26.7)                                   | 11 (73.3)                 | 0.049  |

**Degree I**: no nausea or vomiting
**Degree II**: one or two episodes of nausea and vomiting
**Degree III**: three or four episodes of nausea and vomiting
**Degree IV**: at least five episodes of nausea and vomiting

### Discussion

The results of this study showed that compared with the patients in the control group (using one antiemetic drug), the severity and frequency of postoperative nausea...
and vomiting in patients receiving individualized treatment were significantly reduced in patients undergoing a gynaecological laparoscopic operation under general anaesthesia. Individualized treatment was similar to the control with respect to the overall safety profile.

Despite the use of general multimodal prophylaxis for patients with any risk factors for PONV, the incidence of nausea and vomiting remained high. The incidence of nausea and vomiting was still as high as 60% for gynaecological patients [15]. The results of this study showed that each risk factor increased the incidence of post-operative nausea and vomiting by approximately 20%, which was similar to the results of previous studies. In the control group, the incidence of nausea and vomiting was 77.8%, 68.7%, and 88.2% for those with a risk score of 2, 3, and 4, respectively. In the individualized treatment group, the incidence of nausea and vomiting was 9.1%, 45.7%, and 61.5% for groups with risk scores of 2, 3, and 4, respectively. In the individualized treatment group, the incidence of nausea and vomiting was 9.1%, 45.7%, and 61.5% for groups with risk scores of 2, 3, and 4, respectively. In the individualized treatment group, grade I and II nausea and vomiting mainly occurred, while in the control group, grade III and IV nausea and vomiting mainly occurred, indicating that an individualized treatment strategy can reduce the severity of nausea and vomiting.

The secondary results of this study showed that individualized management strategies were effective in improving vomiting symptoms but not in alleviating nausea, which may be related to the primary use of 5-HT3 antagonists rather than dopamine receptor antagonists in this study. Studies have shown that 5-HT3 antagonists, such as ondansetron, have generally been found to be considerably better at preventing emesis than nausea [11]. In this study, dopamine receptor antagonists were not routinely used but only as part of a remedy for nausea and vomiting. However, dopamine antagonists, such as metoclopramide, are more effective in treating nausea than emesis [16, 17].

This study has several limitations. First, only steroid, 5-HT3 receptor, and anticline antagonists were used in the individualized treatment group in this study, while dopamine receptor antagonists were used only as salvage antiemetic agents, resulting in slight differences in nausea and vomiting relief between the two groups. Second, all patients in the study were female, and the results may therefore not be generalizable to male patients, although this is of limited significance because men are much less frequently at high risk of postoperative nausea and vomiting. However, the evidence that antiemetic drugs with different mechanisms of action exert an additive benefit [14]. Therefore, international guidelines recommend the use of three different types of antiemetic drugs to prevent postoperative nausea and vomiting in high-risk patients.

The study showed that the individualized treatment group did not differ from the control group in the incidence of adverse events such as chills, arrhythmias, and delayed recovery.

Conclusions

In conclusion, this single-centre, double-blind, randomized study suggests that an individualized PONV prophylactic treatment strategy based on the number of PONV risk factors could be a safe and effective regimen to reduce the incidence of PONV in adult patients undergoing laparoscopic gynaecological surgery.

Abbreviations

PONV: Postoperative nausea and vomiting; CR: Complete Response; SD: Standard deviation.

Acknowledgements

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WDY and WJM conceived and designed the study. WJM and MFW performed the experiments. ZY and LC contributed essential materials, and WJM and YPQ analyzed and interpreted the data. All of the authors read and approved the final manuscript.

Funding

First Affiliated Hospital of Wannan Medical College Three New Projects (Y20088), Young and middle-aged project of Wannan Medical College(WK2012F21).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by Ethics Committee of the First Affiliated Hospital of Wannan Medical College, China (No. 2021–06). Written informed consent was obtained from all participants for study participation.

Consent for publication

Written informed consent for publication was obtained from all participants.
Competing interests
The authors declare no conflicts of interest.

Author details
1 Department of Anesthesiology, First Affiliated Hospital of Wannan Medical College, No. 2 Zheshan Street, Wuhu 241000, Anhui, China. 2 Department of Critical Care Medicine, First Affiliated Hospital of Wannan Medical College, No.2 Zheshan Street, Wuhu 241000, Anhui, China.

Received: 26 April 2022    Accepted: 12 August 2022

References
1. Gan TJ. Postoperative nausea and vomiting—can it be eliminated? JAMA. 2002;287(10):1233–6.
2. Frenzel JC, Kee SS, Ensor JE, Riedel BJ, Ruiz JR. Ongoing provision of individual clinician performance data improves practice behavior. Anesth Analg. 2010;111(2):S15–9.
3. Koivuranta M, Läääärä E, Snäre L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52(5):443–9.
4. Habib AS, Chen YT, Taguchi A, Hu XY, Gan TJ. Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis. Curr Med Res Opin. 2006;22(6):1093–9.
5. Kawano H, Ohshita N, Katome K, Kadota T, Kinoshita M, Matsuoka Y, Tsutsui YM, Kawahito T, Kana S, Oshita S. Effects of a novel method of anesthesia combining propofol and volatile anesthesia on the incidence of postoperative nausea and vomiting in patients undergoing laparoscopic gynecological surgery. Braz J Anesthesiol. 2016;66(1):12–8.
6. Apfel CC, Philip BK, Cakmakkaya OS, Shilling A, Shi YY, Leslie JB, Allard M, Turan A, Windle P, Odom-Foren J, et al. Who is at risk for postdischarge nausea and vomiting after ambulatory surgery? Anesthesiology. 2012;117(3):475–86.
7. Apfel CC, Kranke P, Weberhart LH. Comparison of surgical site and patient’s history with a simplified risk score for the prediction of postoperative nausea and vomiting. Anaesthesia. 2004;59(11):1078–82.
8. Leslie K, Myles PS, Chan MT, Paech MJ, Peyton P, Forbes A, McKenzie D. Risk factors for severe postoperative nausea and vomiting in a randomized trial of nitrous oxide-based vs nitrous oxide-free anesthesia. Br J Anaesth. 2008;101(4):498–505.
9. Gan TJ, Belani KG, Bergeese S, Chung F, Demunsch P, Habib AS, Jin Z, Kovac AL, Meyer TA, Utman RD, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411–48.
10. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000;59(2):213–43.
11. Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006;3:4125.
12. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs. 2007;21(10):813–33.
13. Aaum A, Sdbf B. What is the ideal combination antiemetic regimen? - ScienceDirect. Best Pract Res Clin Anaesthesiol. 2020;34(4):701–12.
14. Apfel CC, Korittia K, Abdalla M, Kerger H, Turan A, Vedder I, Zernák C, Danner K, Joketa R, Pocock SJ, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441–51.
15. Apfel CC, Läääärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;91(3):693–700.
16. Henz J, Sonneregger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth. 2000;47(6):537–51.
17. Apfel CC, Cakmakkaya OS, Frings G, Kranke P, Mallotra A, Stader A, Turan A, Biedler A, Koldzec K. Droperidol has comparable clinical efficacy against both nausea and vomiting. Br J Anaesth. 2009;103(3):359–63.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.